Pictet-Biotech -P dy USD

Reference Data

ISIN LU0208607159
Valor Number 2025194
Bloomberg Global ID BBG000PHJBH1
Fund Name Pictet-Biotech -P dy USD
Fund Provider Pictet Asset Management S.A. Genève, Switzerland
Phone: +41 58 323 10 24
www.assetmanagement.pictet
Fund Provider Pictet Asset Management S.A.
Representative in Switzerland Pictet Asset Management S.A.
Genève 73
Phone: +41 58 323 30 00
Distributor(s) Credit Suisse AG
Zürich
Phone: +41 44 333 11 11 UBS AG
Zürich
Phone: +41 44 234 11 11 Vontobel Fonds Services AG
Zürich
Phone: +41 58 283 74 77
Asset Class Equities
EFC Category Equity Health Care
Distribution Policy Distribution
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs.
Peculiarities

Fund Prices

Current Price * 790.30 USD 03.04.2025
Previous Price * 784.00 USD 02.04.2025
52 Week High * 1,033.69 USD 11.11.2024
52 Week Low * 784.00 USD 02.04.2025
NAV * 790.30 USD 03.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 1,203,172,512
Unit/Share Assets *** 3,868,429
Trading Information SIX

Performance

YTD Performance -10.53% 31.12.2024
03.04.2025
YTD Performance (in CHF) -13.08% 31.12.2024
03.04.2025
1 month -10.84% 03.03.2025
03.04.2025
3 months -12.11% 03.01.2025
03.04.2025
6 months -17.16% 03.10.2024
03.04.2025
1 year -12.44% 04.04.2024
03.04.2025
2 years +4.09% 03.04.2023
03.04.2025
3 years +0.43% 04.04.2022
03.04.2025
5 years +10.67% 03.04.2020
03.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI 0.3489
ADDI Date 03.04.2025

Top 10 Holdings ***

Gilead Sciences Inc 6.57%
Insmed Inc 5.17%
argenx SE ADR 4.87%
Regeneron Pharmaceuticals Inc 3.55%
SpringWorks Therapeutics Inc Ordinary Shares 3.08%
Sarepta Therapeutics Inc 3.07%
Alnylam Pharmaceuticals Inc 3.03%
Amgen Inc 2.94%
TG Therapeutics Inc 2.86%
Vaxcyte Inc Ordinary Shares 2.83%
Last data update 28.02.2025

Cost / Risk

TER *** 1.99%
TER date *** 30.09.2024
Performance Fee ***
PTR
Max. Management Fee *** 2.40%
Ongoing Charges *** 1.99%
SRRI ***
SRRI date *** 28.02.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)